Experimental HIV Drugs
Experimental HIV Drugs
Experimental Pharmacoenhancer Cobicistat Matches Ritonavir as Booster
- Details
- Category: Experimental HIV Drugs
- Published on Friday, 05 August 2011 00:00
- Written by Liz Highleyman
The novel boosting agent cobicistat (formerly GS 9350) -- which does not have anti-HIV activity itself -- performed as well as the sole available pharmacoenhancer, ritonavir (Norvir), when combined with atazanavir (Reyataz) plus tenofovir/emtricitabine (the drugs in Truvada), researchers reported in the August 1, 2011, advance online edition of AIDS.
Expert Overview from IAS 2011 [VIDEO]
- Details
- Category: Experimental HIV Drugs
- Published on Friday, 05 August 2011 00:00
- Written by Gregory Fowler
Cal Cohen from the Community Research Institute of New England provides an overview of the 6th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2011) recently held in Rome, including groundbreaking findings on treatment as prevention as well as data on experimental antiretroviral agents and new strategies for using existing drugs.
IAS 2011: New Integrase Inhibitor Dolutegravir Looks Potent and Well-tolerated
- Details
- Category: Experimental HIV Drugs
- Published on Tuesday, 26 July 2011 00:00
- Written by Liz Highleyman
The next-generation HIV integrase inhibitor dolutegravir (S/GSK1349572) suppressed HIV viral load as well as efavirenz (Sustiva) but caused fewer side effects in a study of treatment-naive patients, researchers reported at the 6th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2011) last week in Rome. 
Pipeline Report Shows Good Prospects for People with HIV, HCV, and TB
- Details
- Category: Experimental HIV Drugs
- Published on Friday, 29 July 2011 00:00
- Written by TAG & iBase
An updated summary of experimental therapies for HIV, hepatitis C virus (HCV), and tuberculosis, produced by treatment advocates with i-Base and TAG, shows rapid progress in therapies for HCV and steady progress in the area of HIV.
IAS 2011: New NNRTI Lersivirine Looks Good in Phase 2 Study
- Details
- Category: Experimental HIV Drugs
- Published on Thursday, 21 July 2011 00:00
- Written by Liz Highleyman
Lersivirine, an investigational non-nucleoside reverse transcriptase inhibitor (NNRTI), lowered HIV viral load about as well as efavirenz (Sustiva) for people starting antiretroviral therapy for the first time, researchers reported at the 6th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2011) this week in Rome.
Web Design and Development by